Abbott traded at $104.06 this Tuesday March 24th, decreasing $0.79 or 0.75 percent since the previous trading session. Looking back, over the last four weeks, Abbott lost 9.32 percent. Over the last 12 months, its price fell by 17.15 percent. Looking ahead, we forecast Abbott to be priced at 102.30 by the end of this quarter and at 93.36 in one year, according to Trading Economics global macro models projections and analysts expectations.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.